Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors)

Abstract Metabolic syndrome (MS) is one of the leading risk factors for the development of cardiovascular diseases, type II diabetes mellitus and reproductive system diseases. Currently, not only cardiovascular disease and reproductive history risks related with MS are frequently discussed, but it has been also shown that MS is associated with increased risk of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer, biliary tract cancers and liver cancer for men). Further studies are required to understand the mechanisms of the involvement of MS components in the pathogenesis of malignant neoplasms. Changes in the expression of transcription and growth factors in the peripheral tissues as well as in cancer tissues of patients with MS were revealed. Transcription factors (AMP‐activated protein kinase‐1, STAT3, sterol regulatory element‐binding protein‐1 and peroxisome proliferator‐activated receptor‐γ), leptin and adiponectin receptors seem to be the most promising molecular targets for the therapy of cancers associated with MS.
Source: Asia-Pacific Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research